Cardiovascular Intervention and Therapeutics最新文献_第5页

Insights into balloon pulmonary angioplasty and the WHO functional class of chronic thromboembolic pulmonary hypertension patients: findings from the CTEPH AC registry. 慢性血栓栓塞性肺动脉高压患者球囊肺血管成形术和WHO功能分类的见解：来自CTEPH AC登记的发现

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-01-22 DOI: 10.1007/s12928-025-01095-9

Nobutaka Ikeda, Kohei Masaki, Kazuya Hosokawa, Kouta Funakoshi, Yu Taniguchi, Shiro Adachi, Takumi Inami, Jun Yamashita, Hitoshi Ogino, Ichizo Tsujino, Masaru Hatano, Nobuhiro Yaoita, Hiroto Shimokawahara, Nobuhiro Tanabe, Kayoko Kubota, Ayako Shigeta, Yoshito Ogihara, Koshin Horimoto, Yoshihiro Dohi, Takashi Kawakami, Yuichi Tamura, Koichiro Tatsumi, Kohtaro Abe

{"title":"Insights into balloon pulmonary angioplasty and the WHO functional class of chronic thromboembolic pulmonary hypertension patients: findings from the CTEPH AC registry.","authors":"Nobutaka Ikeda, Kohei Masaki, Kazuya Hosokawa, Kouta Funakoshi, Yu Taniguchi, Shiro Adachi, Takumi Inami, Jun Yamashita, Hitoshi Ogino, Ichizo Tsujino, Masaru Hatano, Nobuhiro Yaoita, Hiroto Shimokawahara, Nobuhiro Tanabe, Kayoko Kubota, Ayako Shigeta, Yoshito Ogihara, Koshin Horimoto, Yoshihiro Dohi, Takashi Kawakami, Yuichi Tamura, Koichiro Tatsumi, Kohtaro Abe","doi":"10.1007/s12928-025-01095-9","DOIUrl":"10.1007/s12928-025-01095-9","url":null,"abstract":"Advances in chronic thromboembolic pulmonary hypertension (CTEPH) treatment have improved prognosis, shifting focus towards symptom management. This study aimed to identify factors influencing the World Health Organization functional class (WHO-FC) in CTEPH patients. The CTEPH AC registry is a prospective, multicenter database from 35 Japanese institutions, analyzing data from August 2018 to July 2023. We examined factors associated with achieving WHO-FC I and WHO-FC changes over time in 1,270 patients. Significant factors for WHO-FC I achievement included male sex (odds ratio: 1.86, p = 0.019), age (0.98, p = 0.007), pulmonary vasodilator use (0.51, p = 0.001), post-balloon pulmonary angioplasty (BPA) (1.93, p = 0.010), lower mean pulmonary arterial pressure (0.94, p = 0.004), and lower pulmonary vascular resistance (PVR) (0.78, p = 0.006). Multivariate analysis showed that WHO-FC improvement correlated with male sex, baseline PVR, and BPA during follow-up. WHO-FC deterioration was associated with cancer, history of pulmonary endarterectomy and/or BPA at registration, bleeding risks, and thyroid disease or hormone therapy. BPA implementation is closely linked to symptomatic improvement and achieving WHO-FC I, while symptom worsening is often associated with patient-specific, difficult-to-control conditions.","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":"689-700"},"PeriodicalIF":3.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenging case of transcatheter patent foramen ovale closure: pitfall by hidden crescent-shaped atrial septal defect. 经导管闭合卵圆孔未闭病例：隐藏的新月形房间隔缺损陷阱。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-02-10 DOI: 10.1007/s12928-025-01101-0

Mitsutaka Nakashima, Teiji Akagi, Takashi Miki, Rie Nakayama, Yoichi Takaya, Shinsuke Yuasa

引用次数: 0

Comparison of very early-phase vascular response to the CD34 antibody‑covered sirolimus‑eluting stent versus durable polymer-coated everolimus-eluting stent. CD34抗体覆盖的西罗莫司洗脱支架与耐用聚合物涂层依维莫司洗脱支架的早期血管反应比较

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-04-18 DOI: 10.1007/s12928-025-01114-9

Hiroki Goto, Hideki Kitahara, Tadahiro Matsumoto, Kazuya Tateishi, Yuichi Saito, Ken Kato, Yoshio Kobayashi

{"title":"Comparison of very early-phase vascular response to the CD34 antibody‑covered sirolimus‑eluting stent versus durable polymer-coated everolimus-eluting stent.","authors":"Hiroki Goto, Hideki Kitahara, Tadahiro Matsumoto, Kazuya Tateishi, Yuichi Saito, Ken Kato, Yoshio Kobayashi","doi":"10.1007/s12928-025-01114-9","DOIUrl":"10.1007/s12928-025-01114-9","url":null,"abstract":"The COMBO stent is a unique biodegradable polymer sirolimus-eluting stent with an anti-CD34 antibody coating that captures endothelial progenitor cells and potentially promotes vessel healing. There are limited data regarding strut tissue coverage at the very short-term period after COMBO stent implantation compared to other types of drug-eluting stents in the same patient. This prospective study enrolled patients who had COMBO Plus stent and durable polymer-coated everolimus-eluting stent (XIENCE stent) implanted simultaneously in the same vessel for long coronary lesions. Strut tissue coverage within 1 month after implantation was compared using optical coherence tomography. Struts fully covered with tissue were defined as covered, and healthy tissue coverage was defined as tissue thickness with ≥ 40 μm. A total of 21 patients, 11 (52%) of whom presented with acute coronary syndrome, were enrolled. A total of 4798 struts from 21 COMBO Plus stents and 4608 struts from 21 XIENCE stents were analyzed at an average of 19.8 ± 6.5 days after implantation. In the lesion-level analysis, covered struts were more frequently observed (83.7 ± 7.4% vs. 76.9 ± 11.0%, P < 0.01), and the rate of healthy tissue coverage tended to be higher (49.9 ± 17.7% vs. 42.1 ± 20.5%, P = 0.07) in the COMBO Plus stent compared to the XIENCE stent. Strut tissue coverage was more advanced in the COMBO Plus stent compared to the XIENCE stent at the very short-term period after implantation.","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":"527-535"},"PeriodicalIF":3.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcatheter aortic valve implantation in elderly patients with severe aortic stenosis and rheumatic phenotype. 经导管主动脉瓣植入术治疗老年严重主动脉瓣狭窄伴风湿表型患者。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-03-31 DOI: 10.1007/s12928-025-01113-w

Ahmed Abdelrahman Elkaialy, Nabil Farag, Ahmad Elsayed Mostafa, Mahmoud Baraka, Diaa Kamal

{"title":"Transcatheter aortic valve implantation in elderly patients with severe aortic stenosis and rheumatic phenotype.","authors":"Ahmed Abdelrahman Elkaialy, Nabil Farag, Ahmad Elsayed Mostafa, Mahmoud Baraka, Diaa Kamal","doi":"10.1007/s12928-025-01113-w","DOIUrl":"10.1007/s12928-025-01113-w","url":null,"abstract":"Significant fibrosis is characteristic of rheumatic aortic valve disease that affects anchoring and deployment of the trans-catheter heart valve. Our goal was to determine whether trans-catheter aortic valve implantation (TAVI) is an effective treatment option for severe aortic stenosis patients with rheumatic valvular disease. This study is a prospective cohort study that includes a total of 54 rheumatic severe aortic stenosis patients who were referred for TAVI. The age ranged from 65.00 to 83.00 years (mean age 72.75 ± 5.86 years). Notably, 63% of the patients had undergone preimplantation balloon dilatation. The outcomes included total new conduction disturbances (transient and permanent defects of atrio-ventricular block and left bundle branch block) in 31.4% of the patients, permanent pacemaker implantation in 3.7%, and valve embolization in 1.85%, and no patients had moderate to severe para-valvular leak. All-cause death within a 6-month follow-up was 3.7%. This cohort was then compared to a propensity score matched group of degenerative calcific severe aortic stenosis of 54 cases revealing comparable post-procedural results. Compared with the outcomes of TAVI in patients with degenerative aortic stenosis, TAVI represents a viable and durable option for rheumatic severe aortic stenosis patients.","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":"632-643"},"PeriodicalIF":3.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful percutaneous catheter thrombectomy for acute axillary artery occlusion. 急性腋窝动脉闭塞经皮导管取栓成功。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-02-17 DOI: 10.1007/s12928-025-01104-x

Yushi Oyama, Keishiro Okawa, Takuya Miyagi, Takahiro Sakai, Kyuhachi Otagiri, Hiroshi Kitabayashi

引用次数: 0

A case of hemolytic anemia after implantation of Sapien3 Ultra RESILIA requiring post-dilation. Sapien3 Ultra RESILIA植入后需要扩张后溶血性贫血1例。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-03-31 DOI: 10.1007/s12928-025-01120-x

Atsushi Iizuka, Harutoshi Tamura, Shunsuke Edamura, Satoshi Nishiyama, Tetsu Watanabe, Masafumi Watanabe

引用次数: 0

Successful transcatheter closure of atrial septal defect with gore cardioform atrial septal defect occluder in an adult patient with anomalous origin of left coronary circumflex artery. 用gore心状房间隔缺损封堵器经导管成功封闭左冠状旋流动脉异常成人房间隔缺损1例。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-04-05 DOI: 10.1007/s12928-025-01122-9

Soshun Asakawa, Takamori Kakino, Ichiro Sakamoto, Akiko Nishizaki, Ayako Ishikita, Kohtaro Abe

引用次数: 0

Prognostic value of HELT-E₂S₂ score among patients undergoing percutaneous coronary intervention: sub-analysis of the SHINANO 5-year registry. 经皮冠状动脉介入治疗患者 HELT-E2S2 评分的预后价值：SHINANO 5 年登记的子分析。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-03-29 DOI: 10.1007/s12928-025-01123-8

Daisuke Sunohara, Tatsuya Saigusa, Yasushi Ueki, Masatoshi Minamisawa, Tadashi Itagaki, Yoshiteru Okina, Kiu Tanaka, Hidetomo Nomi, Tamon Kato, Soichiro Ebisawa, Takashi Miura, Koichiro Kuwahara

{"title":"Prognostic value of HELT-E2S2 score among patients undergoing percutaneous coronary intervention: sub-analysis of the SHINANO 5-year registry.","authors":"Daisuke Sunohara, Tatsuya Saigusa, Yasushi Ueki, Masatoshi Minamisawa, Tadashi Itagaki, Yoshiteru Okina, Kiu Tanaka, Hidetomo Nomi, Tamon Kato, Soichiro Ebisawa, Takashi Miura, Koichiro Kuwahara","doi":"10.1007/s12928-025-01123-8","DOIUrl":"10.1007/s12928-025-01123-8","url":null,"abstract":"The HELT-E2S2 score has recently been proposed as a new risk stratification tool for ischemic stroke in Japanese patients with atrial fibrillation (AF). We aimed to evaluate the prognostic value of HELT-E2S2 score for cardiovascular events among patients undergoing percutaneous coronary intervention (PCI). Between August 2012 and July 2013, patients undergoing PCI enrolled in the SHINANO 5-year registry, a prospective, observational multicenter registry, were analyzed for the current study. Primary endpoint was major adverse cardiovascular events (MACE), a composite of all-cause death, myocardial infarction, and ischemic stroke at 5 years. Key secondary endpoint was bleeding events at 5 years. A total of 1608 patients were divided into the low HELT-E2S2 score group (< 2, n = 915) and high HELT-E2S2 score group (≥ 2, n = 693). Major criteria of the HELT-E2S2 score were hypertension (74.7%), elderly age 75-84 years (31.3%), and AF (11.1%). Kaplan-Meier analysis revealed that the high HELT-E2S2 score group had a significantly higher incidence of MACE (33.4% vs. 14.8%, P < 0.001) and bleeding events (12.7% vs. 5.3%, P < 0.001) compared with the low HELT-E2S2 score group. Multivariable analysis demonstrated that the HELT-E2S2 score remained significantly associated with MACE (hazard ratio: 1.73, 95% confidence interval: 1.11-2.69; P = 0.015). The HELT-E2S2 score appears a useful tool for predicting future cardiovascular events in CAD patients undergoing PCI.","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":"544-552"},"PeriodicalIF":3.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When brain and heart collide: a deeper dive into treatment pathways of stroke complicating TAVI. 当大脑和心脏发生碰撞：深入探究 TAVI 并发脑卒中的治疗途径。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-07-01 Epub Date: 2025-03-29 DOI: 10.1007/s12928-025-01121-w

Mark Kheifets, Boris Kruchin, Guy Witberg, Tsahi T Lerman, Rani Barnea, Michael Findler, Ran Brauner, Leor Perl, Pablo Codner, Yeela Talmor-Barkan, Guy Rephaeli, Eitan Auriel, Ran Kornowski, Amos Levi

{"title":"When brain and heart collide: a deeper dive into treatment pathways of stroke complicating TAVI.","authors":"Mark Kheifets, Boris Kruchin, Guy Witberg, Tsahi T Lerman, Rani Barnea, Michael Findler, Ran Brauner, Leor Perl, Pablo Codner, Yeela Talmor-Barkan, Guy Rephaeli, Eitan Auriel, Ran Kornowski, Amos Levi","doi":"10.1007/s12928-025-01121-w","DOIUrl":"10.1007/s12928-025-01121-w","url":null,"abstract":"Periprocedural ischemic stroke remains a major concern of transcatheter aortic valve implantation (TAVI). The aims of this study were to describe the incidence, characteristic, and outcomes of patients presenting with acute ischemic stroke complicating TAVI (AISCT), and to compare conservative management (CM) vs. neurointervention (NI), in eligible patients. We analyzed consecutive TAVI procedures performed in the Rabin Medical Center between 2008 and 2021. The patients with and without AISCT were compared. Outcomes of NI following AISCT were compared to CM. The primary outcomes were mortality at 1 and 3 years and neurologic disability status at 3 months. Of 1515 eligible patients who underwent TAVI between 2008 and 2021, 38 (2.5%) had AISCT within 30 days. All-cause mortality was significantly higher in the AISCT group in 30 days (13.9% vs. 2.4%, p < 0.01), 1 year (27.8% vs. 8.1%, p < 0.01), and 3 years (49.0% vs. 26.8%, p < 0.01), as compared to the AISCT negative group. Out of the 38 patients who suffered AISCT between 2008 and 2021, 7 underwent NI. The majority of AISCT were observed within the first 24-h following TAVI (p < 0.01). All-cause mortality following moderate/severe stroke was significantly higher (p = 0.037) compared to mild stroke. As compared to the CM, NI was not found to reduce mortality. However, patients with moderate severity stroke who underwent NI enjoyed a higher rate of disability free survival at 3 months (100% vs. 40%, p = 0.044), compared to patients treated conservatively. NI, as compared to CM, may improve disability status in eligible patients with moderate stroke.","PeriodicalId":9439,"journal":{"name":"Cardiovascular Intervention and Therapeutics","volume":" ","pages":"657-668"},"PeriodicalIF":3.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12167299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The novel strategy to acute coronary syndrome with resistant massive thrombus. 急性冠脉综合征伴顽固性大块血栓的新治疗策略。

IF 3.1

Cardiovascular Intervention and Therapeutics Pub Date : 2025-06-29 DOI: 10.1007/s12928-025-01148-z

Satoshi Kanai, Shinya Fujii, Teruhiko Suzuki, Takashi Miyamoto

引用次数: 0